Avantor reports Q3 adjusted EPS 26c, consensus 25c

Reports Q3 revenue $1.71B, consensus $1.73B. “Our team delivered another quarter of solid financial results, including outperformance in bioprocessing and a return to growth in our laboratory solutions segment. Our disciplined approach to working capital drove another quarter of best-in-class free cash flow conversion and we are raising our free cash flow guidance for the year,” said Michael Stubblefield, president and CEO.